Agenus selected for late-breaking oral presentation at esmo-gi

Lexington, mass.--(business wire)--agenus (nasdaq: agen), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional ctla-4 antibody) in combination with balstilimab (pd-1 antibody) for patients with non-microsatellite instability-high metastatic colorectal cancer (non-msi-h mcrc) has been selected for a late-breaking oral presentation at the upcoming esmo world congress on ga.
AGEN Ratings Summary
AGEN Quant Ranking